I’ve been following ABT and the returns of some of its competitors for the past few weeks. In the past week, Chromadex is down 5.7%, CIGX is up 3.2%, RHHBY is up 3%, VVUS is up 3.7%, ARNA is up 3.4%, and ABT is up 2.3%. Does anyone know why ABT was only up 2.3% and why Chromadex was down 5.7%?
As with the other two comments, I agree that the title of this post is just a goofy argument put forth by holders of companies like Vivus and Arena Pharmaceuticals. Natural supplements are a thing of the future. Get used to it. Companies like Chromadex are going to take their share of the market, and at the same time probably expand the existing market to a new groups of people. I advise all involved in the weight loss/obesity arena to hold Chromadex, Vivus, and Arena – but don’t leave the natural supplements out. They have a continued bright revenue future.
Has an owner of Roche’s stock read the article: “Vivus: Qnexa is Not Guaranteed Approval. Remember Provenge? The article addresses the weight loss/obesity marketplace. Is anyone on this blog concerned about the effect Chromadex could have on the entire weight loss/obesity drug market as a whole? Do you think Roche would be adversely affected by potential positive results to be released in the next few weeks? From what I understand, Roche is a direct competitor.